Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819197 | 0.87 | L3MBTL1 (0.44) | MAOBL3MBTL1MEN1KMT2ASQOR | |
| SCHEMBL25819100 | 0.86 | L3MBTL1 (0.43) | L3MBTL1SQORPDE5ACNR1 | |
| SCHEMBL30112435 | 0.86 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL24873214 | 0.86 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL26044686 | 0.85 | MEN1 (0.48) | L3MBTL1MEN1KMT2ASQORPDE5A | |
| SCHEMBL25819183 | 0.81 | AR (0.44) | L3MBTL1MEN1KMT2ASQORCNR1 | |
| SCHEMBL29013129 | 0.80 | GABRG2 (0.52) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL25819126 | 0.79 | L3MBTL1 (0.47) | L3MBTL1SQORCNR1 | |
| SCHEMBL25819597 | 0.79 | L3MBTL1 (0.42) | L3MBTL1MEN1KMT2ASQORCNR1 | |
| SCHEMBL25482306 | 0.79 | DYRK1A (0.44) | L3MBTL1SQOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | GABRG2 4427/4885GABRB3 4065/4885GABRA5 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.